Isis Pharmaceuticals (ISIS -8%) gets hit after its Q3 report falls wide of the mark. Revenue...

|By:, SA News Editor

Isis Pharmaceuticals (ISIS -8%) gets hit after its Q3 report falls wide of the mark. Revenue plummeted 43% Y/Y due to the volatility of its income stream, which largely consists of licensing fees, milestone payments and other similar billing arrangements.